Related Experiment Video
Updated: May 22, 2025
10:10
Quantifying Cognitive Decrements Caused by Cranial Radiotherapy
Published on: October 18, 2011
12.6K
Chemotherapy-related cognitive impairment and kidney dysfunction.
Mariadelina Simeoni1, Michele M Mulholland2, Biruh T Workeneh2
1Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli", Caserta, Italy.
Summary
Cancer and kidney disease (KD) worsen cognitive impairment in patients undergoing chemotherapy. This review explores how KD may exacerbate chemotherapy-related cognitive impairment (CRCI) through shared mechanisms.
Area of Science:
- Nephrology
- Oncology
- Neuroscience
Background:
- Cancer and kidney diseases (KD) frequently coexist, leading to poorer patient outcomes.
- Both cancer and KD are independently associated with cognitive impairment.
- Chemotherapy-related cognitive impairment (CRCI) is a common side effect of cancer treatment, manifesting as attention deficits and memory problems.
Purpose of the Study:
- To review the phenomenon of CRCI.
- To investigate the potential impact of KD on CRCI.
- To explore shared pathogenetic mechanisms, clinical presentations, and imaging findings between cognitive impairment in KD and CRCI.
Main Methods:
- Literature review of existing studies on CRCI and cognitive impairment in KD.
- Analysis of shared biological pathways, including neurotoxicity, neuroinflammation, oxidative stress, vascular disease, and electrolyte/acid-base imbalances.
- Examination of the role of the blood-brain barrier disruption in enhancing neurotoxicity.
Main Results:
- Shared mechanisms suggest a potential for heightened neurotoxicity of antineoplastic drugs in cancer patients with KD.
- Cognitive impairment may be synergistically potentiated in cancer patients with coexisting KD.
- Disruption of the blood-brain barrier may increase brain permeability to chemotherapy drugs in these patients.
Conclusions:
- Cancer patients with KD may be at increased risk for severe CRCI.
- Shared pathophysiological pathways underscore the link between KD, cancer, and cognitive dysfunction.
- Further translational research is essential to confirm these findings and develop targeted interventions.
Related Concept Videos
01:17Factors Affecting Renal Clearance: Renal Impairment
46
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
46
01:11Renal Failure: Dose Adjustments
52
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
52
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
146
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
146
02:49Cancer Therapies
7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K
01:31Factors Affecting Renal Clearance: Drug's Physicochemical Properties and Plasma Levels
156
Renal clearance of a drug is influenced by various factors, including its physicochemical properties and plasma levels. These factors play a significant role in determining how efficiently the kidneys eliminate a drug.
One important factor is the drug's molecular size. The kidneys readily excrete smaller molecules below 300 Daltons (Da). On the other hand, molecules weighing between 300 and 500 Da are excreted through both urine and bile. Larger molecules above 500 Da tend to be excreted...
One important factor is the drug's molecular size. The kidneys readily excrete smaller molecules below 300 Daltons (Da). On the other hand, molecules weighing between 300 and 500 Da are excreted through both urine and bile. Larger molecules above 500 Da tend to be excreted...
156
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
171
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
171